Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials

Authors

Joann E. Manson, Harvard Medical School
Rowan T. Chlebowski, University of California, Los Angeles
Marcia L. Stefanick, Stanford UniversityFollow
Aaron K. Aragaki, Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA
Jacques E. Rossouw, National Institutes of Health, Bethesda, MD
Lisa W. Martin, George Washington UniversityFollow
+25 additional authors

Document Type

Response or Comment

Publication Date

2013

Journal

JAMA - Journal of the American Medical Association

Volume

Volume 310, Issue 13

Inclusive Pages

1353-1368

Keywords

Breast Neoplasms--prevention & control; Coronary Disease--prevention & control; Estrogens--adminstration & dosage; Estrogens; Conjugated (USP)--administration & dosage; Hormone Replacement Therapy--adverse effects; Medroxyprogesterone Acetate--administration & dosage

Comments

This is an open access article. Click on link for full-text access.

APA Citation

anson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials. JAMA - Journal of the American Medical Association, 310(13), 1353-1368.

Peer Reviewed

1

Open Access

1